Kewaunee Scientific Reports 17% Revenue Growth, $20M Debt Reduction, Despite Earnings Dip
KEQU is trading near its 52-week low of $33.7 (4.7% above the low) on elevated volume (3.9× avg).
Summary
Kewaunee Scientific reported fiscal year 2026 results, showing a 17.3% increase in sales to $281.999 million. Despite this strong top-line growth, net earnings declined to $9.618 million and diluted EPS fell to $3.22. The company significantly strengthened its balance sheet by reducing long-term debt by $20 million and fully repaying seller notes, building on the debt repayment noted in the prior 10-Q. This mixed report highlights robust revenue and improved financial stability through debt reduction, but also indicates profitability challenges that could concern investors.
At the time of this announcement, KEQU was trading at $35.28 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $101.1M. The 52-week trading range was $33.70 to $60.89. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: PR Newswire.